Your browser doesn't support javascript.
loading
Implementation of an HIV-1 Triple-Target NAT Assay in the Routine Screening at Three German Red Cross Blood Centres.
Zolt, Silke De; Thermann, Rolf; Bangsow, Thorsten; Pichl, Lutz; Müller, Benjamin; Jork, Christine; Weber-Schehl, Marijke; Hedges, Doris; Schupp, Ingo; Unverzagt, Patrick; de Rue, Katrin; Roth, W Kurt.
Afiliación
  • Zolt SD; Gesellschaft zur Forschung, Entwicklung und Distribution von Diagnostika im Blutspendewesen mbH (GFE Blut), Frankfurt/M., Germany.
  • Thermann R; Gesellschaft zur Forschung, Entwicklung und Distribution von Diagnostika im Blutspendewesen mbH (GFE Blut), Frankfurt/M., Germany.
  • Bangsow T; Gesellschaft zur Forschung, Entwicklung und Distribution von Diagnostika im Blutspendewesen mbH (GFE Blut), Frankfurt/M., Germany.
  • Pichl L; DRK Blutspendedienst West, Hagen, Germany.
  • Müller B; DRK Blutspendedienst West, Hagen, Germany.
  • Jork C; DRK Blutspendedienst NSTOB, Springe, Germany.
  • Weber-Schehl M; Blutspendedienst des Bayerischen Roten Kreuzes, Wiesentheid, Germany.
  • Hedges D; Blutspendedienst des Bayerischen Roten Kreuzes, Wiesentheid, Germany.
  • Schupp I; Gesellschaft zur Forschung, Entwicklung und Distribution von Diagnostika im Blutspendewesen mbH (GFE Blut), Frankfurt/M., Germany.
  • Unverzagt P; Gesellschaft zur Forschung, Entwicklung und Distribution von Diagnostika im Blutspendewesen mbH (GFE Blut), Frankfurt/M., Germany.
  • de Rue K; Gesellschaft zur Forschung, Entwicklung und Distribution von Diagnostika im Blutspendewesen mbH (GFE Blut), Frankfurt/M., Germany.
  • Roth WK; Gesellschaft zur Forschung, Entwicklung und Distribution von Diagnostika im Blutspendewesen mbH (GFE Blut), Frankfurt/M., Germany.
Transfus Med Hemother ; 43(3): 183-9, 2016 May.
Article en En | MEDLINE | ID: mdl-27403090
BACKGROUND: Blood product safety was significantly improved by the introduction of NAT testing in the late 1990s, resulting in a strong decrease of transfusion-transmitted infections (TTIs). Due to the occurrence of HIV-1 NAT test failures as a consequence of mismatch mutations in the amplicon regions of mono-target NAT assays, the Paul Ehrlich Institute mandated the implementation of multi-target NAT assays for HIV-1 in 2014. Commercial suppliers mostly developed dual-target NAT assays, with only one implementing a triple-target NAT assay. METHODS: The HIV-1 triple-target NAT assay v3 (GFE Blut) was tested on mutated specimens and synthetic DNA bearing mutations that resulted in sample underquantification or false-negative test results. In addition, data from 2 years routine testing at three German Red Cross Blood centres were analysed. RESULTS: The HIV-1 triple-target PCR could compensate for all mutations tested and could compensate the loss of one amplicon without a significant loss of sensitivity. Data from 2 years routine testing showed a solid performance. CONCLUSION: The HIV-1 triple-target v3 assay (GFE Blut) can compensate mutations in target sequences better than a dual-target assay and is applicable to high-throughput screening, thus increasing blood product safety.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: Transfus Med Hemother Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: Transfus Med Hemother Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza